South Dakota statute
SDCL § 34-20B-16 — Substances included in Schedule II
Current through text effective June 30, 2026 (through the 2025 Regular Session)
Part of Chapter 20B: Drugs And Substances Control, South Dakota Codified Laws.
Full text of SDCL § 34-20B-16
Statutory text current through the text effective June 30, 2026 (through the 2025 Regular Session). This publication reproduces the official statutory text; it is not the official statutes of the State of South Dakota.
Any of the following substances, including their salts, isomers, and salts of isomers, is included in Schedule II except those narcotic drugs listed in other schedules, whether produced directly or indirectly by extraction from substances of vegetable origin, independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:
(1) Opium (except when it meets the requirements of subdivision 34-20B-23(7) or 34-20B-26(5)), coca leaves, and opiate;
(2) Any salt, compound, derivative, or preparation of opium, coca leaves (including cocaine), or opiate, excluding apomorphine, dextrorphan, naloxone, naloxegol, naldemedine, nalbuphine, nalmefene, naltrexone, 6ß-naltrexol, and samidorphan;
(3) Any salt, compound, derivative, or preparation thereof that is chemically equivalent or identical with any of the substances referred to in subdivisions (1) and (2), except that these substances may not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine; and may not include the isoquinoline alkaloids of opium;
(4) Opium poppy and poppy straw;
(5) Amphetamine;
(6) Methamphetamine;
(7) Amobarbital;
(8) Pentobarbital;
(9) Secobarbital;
(10) Methylphenidate;
(11) Phenmetrazine;
(12) Etorphine;
(13) Diprenorphine;
(14) Deleted by SL 2000, ch 170, § 1;
(15) Nabilone;
(16) Glutethimide;
(17) Phencyclidine immediate precursors:
(a) 1-phenylcyclohexylamine;
(b) 1-piperidinocyclohexanecarbonitrile (PCC);
(18) Lisdexamfetamine, its salts, isomers, and salts of its isomers;
(19) Tapentadol; and
(20) Dronabinol [(-)-delta-9-trans tetrahydrocannabinol] in an oral solution in a drug product approved for marketing by the United States Food and Drug Administration.
Official sources
Legal terms used in this section
This reference is informational and is not legal advice.